title: Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis.
abstract: OBJECTIVE
  To compare the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis for the reduction of recurrent thromboembolic events, death, extension of thrombus, and haemorrhages.
  
  
  METHODS
  Meta-analysis of results from 16 randomised controlled clinical studies.
  
  
  METHODS
  2045 patients with established deep venous thrombosis.
  
  
  METHODS
  Treatment with low molecular weight heparins or unfractionated heparin.
  
  
  METHODS
  Incidences of thromboembolic events (deep venous thrombosis or pulmonary embolism, or both); major haemorrhages; total mortality; and extension of thrombus.
  
  
  RESULTS
  A significant reduction in the incidence of thrombus extension (common odds ratio 0.51, 95% confidence interval 0.32 to 0.83; P = 0.006) in favour of low molecular weight heparin was observed. Non-significant trends also in favour of the low molecular weight heparins were observed for the recurrence of thromboembolic events (0.66, 0.41 to 1.07; P = 0.09), major haemorrhages (0.65, 0.36 to 1.16; P = 0.15), and total mortality (0.72, 0.46 to 1.4; P = 0.16).
  
  
  CONCLUSIONS
  Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in the treatment of venous thrombosis. These results, however, remain to be confirmed by using clinical outcomes in suitably powered clinical trials.
authors.affiliation: Service de Pharmacologie Clinique, Lyons, France.
authors.forename: A
authors.initials: A
authors.lastname: Leizorovicz
authors.forename: G
authors.initials: G
authors.lastname: Simonneau
authors.forename: H
authors.initials: H
authors.lastname: Decousus
authors.forename: J P
authors.initials: JP
authors.lastname: Boissel
mesh_terms: D004305:Dose-Response Relationship, Drug; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D016017:Odds Ratio; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D013924:Thrombophlebitis / Q000188:drug therapy* / Q000401:mortality
chemical_list: D006495:Heparin, Low-Molecular-Weight; D006493:Heparin